"失败的Fontans:"在儿科中是一个新兴的挑战
Tracy Hills1, Erika Mejia2, Rachna May3
1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Cardiology in the young
|December 29, 2025
概括
随着越来越多的患有低可塑性左心综合征的患者活到成年,医疗保健提供者面临着管理"失败的Fontan"生理学的挑战. 本案例报告探讨了儿科息护理如何支持这些复杂的成年患者.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 抚慰性护理医学 抚慰性护理医学
- 遗传性心脏病管理与管理
背景情况:
- 低可塑性左心综合征 (HLHS) 的分阶段缓解性手术缓解改善了生存率.
- 现在越来越多的成年人出现了"失败的Fontan"生理学,这带来了独特的临床挑战.
研究的目的:
- 讨论儿科息护理在支持患有"失败的Fontan"生理学的成年患者中的作用和各种应用.
- 突出HLHS幸存者的不断变化的需求进入成年期.
主要方法:
- 这是一个简短的案例报告.
- 讨论临床管理策略.
- 对息护理干预措施的审查.
主要成果:
- 提供者越来越多地遇到"失败的Fontan"生理学的成年患者.
- 儿科息护理为这一群体提供了多方面的支持.
- 早期整合息护理可以改善生活质量.
结论:
- 对于HLHS患者的长期生存,需要专门的护理模式.
- 儿科息治疗对于管理复杂的症状和改善成年人"失败的Fontan"生理学的结果至关重要.
- 跨学科的合作是解决这个不断增长的患者群体需求的关键.
相关概念视频
Acute Respiratory Failure-III
722
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
722
Acute Respiratory Failure-V
413
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
413
Acute Respiratory Failure-I
784
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
784
Acute Respiratory Failure-II
980
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
980
Heart Failure II: Pathophysiology
663
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
663
Heart Failure VI: Adjunct Therapies
233
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233


